• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Preliminary results of the association of Palbociclib and radiotherapy in metastatic breast cancer patients.

作者信息

Hans Sophie, Cottu Paul, Kirova Youlia M

机构信息

Institut Curie, Paris, France.

Institut Curie, Paris, France.

出版信息

Radiother Oncol. 2018 Jan;126(1):181. doi: 10.1016/j.radonc.2017.09.010. Epub 2017 Sep 27.

DOI:10.1016/j.radonc.2017.09.010
PMID:28964534
Abstract
摘要

相似文献

1
Preliminary results of the association of Palbociclib and radiotherapy in metastatic breast cancer patients.帕博西尼与放疗联合用于转移性乳腺癌患者的初步结果。
Radiother Oncol. 2018 Jan;126(1):181. doi: 10.1016/j.radonc.2017.09.010. Epub 2017 Sep 27.
2
Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer.帕博西尼治疗广泛预处理的转移性 ER 阳性 HER2 阴性乳腺癌。
Breast Cancer Res Treat. 2018 Aug;171(1):131-141. doi: 10.1007/s10549-018-4827-6. Epub 2018 May 16.
3
Concurrent radiotherapy with palbociclib or ribociclib for metastatic breast cancer patients: Preliminary assessment of toxicity.帕博西尼或瑞博西尼联合放疗治疗转移性乳腺癌患者的初步毒性评估。
Breast. 2019 Aug;46:70-74. doi: 10.1016/j.breast.2019.05.001. Epub 2019 May 8.
4
Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval.帕博西尼处方模式的真实世界证据分析：美国社区肿瘤实践中批准上市后一年治疗晚期/转移性乳腺癌患者。
Breast Cancer Res. 2018 May 2;20(1):37. doi: 10.1186/s13058-018-0958-2.
5
Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2- metastatic breast cancer.帕博西尼在 HR+/HER2-转移性乳腺癌中经大量预处理的患者中的疗效和安全性。
Future Oncol. 2018 Mar;14(6):537-544. doi: 10.2217/fon-2017-0491. Epub 2017 Nov 22.
6
Palbociclib-Induced Posterior Reversible Encephalopathy Syndrome: A Previously Unreported Toxicity.帕博西尼诱发的后部可逆性脑病综合征：一种此前未报道的毒性反应。
J Oncol Pract. 2019 Feb;15(2):119-121. doi: 10.1200/JOP.18.00643.
7
The safety of palbociclib for the treatment of advanced breast cancer.帕博西尼治疗晚期乳腺癌的安全性。
Expert Opin Drug Saf. 2018 Mar;17(3):325-330. doi: 10.1080/14740338.2018.1429402. Epub 2018 Jan 28.
8
CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.CDK4/6 抑制剂帕博西尼（PD0332991）治疗 Rb+晚期乳腺癌：Ⅱ期活性、安全性和预测性生物标志物评估。
Clin Cancer Res. 2015 Mar 1;21(5):995-1001. doi: 10.1158/1078-0432.CCR-14-2258. Epub 2014 Dec 11.
9
Palbociclib: first global approval.帕博西尼：全球首次批准。
Drugs. 2015 Apr;75(5):543-51. doi: 10.1007/s40265-015-0379-9.
10
Cutaneous and Gastrointestinal Leukocytoclastic Vasculitis Induced by Palbociclib in a Metastatic Breast Cancer Patient: A Case Report.哌柏西利诱发转移性乳腺癌患者皮肤及胃肠道白细胞破碎性血管炎：一例报告
Clin Breast Cancer. 2018 Oct;18(5):e755-e758. doi: 10.1016/j.clbc.2018.07.006. Epub 2018 Aug 16.

引用本文的文献

1
Radiosensitizing effects of CDK4/6 inhibitors in hormone receptor-positive and HER2-negative breast cancer mediated downregulation of DNA repair mechanism and NF-κB-signaling pathway.细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制剂在激素受体阳性且人表皮生长因子受体2（HER2）阴性乳腺癌中的放射增敏作用介导了DNA修复机制和核因子κB（NF-κB）信号通路的下调。
Transl Oncol. 2024 Nov;49:102092. doi: 10.1016/j.tranon.2024.102092. Epub 2024 Aug 16.
2
Locoregional Radiotherapy in Patients with Advanced Breast Cancer Treated with Cyclin-Dependent Kinase 4/6 Inhibitors Based on Real-World Data.基于真实世界数据的细胞周期蛋白依赖性激酶4/6抑制剂治疗晚期乳腺癌患者的局部区域放疗
Pharmaceuticals (Basel). 2024 Jul 11;17(7):927. doi: 10.3390/ph17070927.
3
Integration of Postoperative Radiation Therapy with Cyclin-Dependent Kinase (CDK) Inhibitors.
术后放疗与细胞周期蛋白依赖性激酶（CDK）抑制剂的联合应用。
Curr Oncol Rep. 2023 Oct;25(10):1153-1159. doi: 10.1007/s11912-023-01444-y. Epub 2023 Aug 25.
4
Safety of CDK4/6 Inhibitors Combined with Radiotherapy in Patients with Metastatic Breast Cancer: A Review of the Literature.CDK4/6 抑制剂联合放疗治疗转移性乳腺癌患者的安全性：文献复习。
Curr Oncol. 2023 Jun 6;30(6):5485-5496. doi: 10.3390/curroncol30060415.
5
Management of Oligometastatic Breast Cancer: An Expert Committee's Opinion.寡转移乳腺癌的管理：专家委员会的意见。
Curr Oncol. 2023 Jan 19;30(2):1416-1425. doi: 10.3390/curroncol30020108.
6
Safety and Feasibility of Radiation Therapy Combined with CDK 4/6 Inhibitors in the Management of Advanced Breast Cancer.放射治疗联合CDK 4/6抑制剂治疗晚期乳腺癌的安全性与可行性
Cancers (Basel). 2023 Jan 22;15(3):690. doi: 10.3390/cancers15030690.
7
Safety and Tolerability of Metastasis-Directed Radiation Therapy in the Era of Evolving Systemic, Immune, and Targeted Therapies.在不断发展的全身治疗、免疫治疗和靶向治疗时代，转移灶定向放射治疗的安全性和耐受性
Adv Radiat Oncol. 2022 Jul 14;7(6):101022. doi: 10.1016/j.adro.2022.101022. eCollection 2022 Nov-Dec.
8
The role of radiation therapy and systemic therapies in elderly with breast cancer.放射治疗和全身治疗在老年乳腺癌患者中的作用。
Transl Cancer Res. 2020 Jan;9(Suppl 1):S97-S109. doi: 10.21037/tcr.2019.07.04.
9
Novel Combinatorial Strategy Using Thermal Inkjet Bioprinting, Chemotherapy, and Radiation on Human Breast Cancer Cells; an In-Vitro Cell Viability Assessment.使用热喷墨生物打印、化疗和放疗对人乳腺癌细胞的新型联合策略；体外细胞活力评估。
Materials (Basel). 2021 Dec 19;14(24):7864. doi: 10.3390/ma14247864.
10
Combination of Modern Radiotherapy and New Targeted Treatments for Breast Cancer Management.现代放射疗法与新型靶向治疗联合用于乳腺癌管理
Cancers (Basel). 2021 Dec 18;13(24):6358. doi: 10.3390/cancers13246358.